Allogene Therapeutics, Inc. (NASDAQ:ALLO) Stock Has Average Target Price of $8.30

Posted by Francis Steltz on Nov 4th, 2026

Shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO – Get Free Report) have been assigned an average recommendation of “Moderate Buy” from the fourteen ratings firms that are currently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, three have assigned a hold rating, eight have assigned a buy rating and two have given a strong buy rating to the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $8.30.

A number of equities research analysts have issued reports on ALLO shares. Weiss Ratings raised Allogene Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, October 21st. Citizens Jmp reissued a “market outperform” rating and set a $6.00 price objective on shares of Allogene Therapeutics in a research report on Monday, August 17th. Finally, William Blair upgraded shares of Allogene Therapeutics to a “strong-buy” rating in a research note on Wednesday, September 23rd.

Read Our Latest Stock Analysis on Allogene Therapeutics

Allogene Therapeutics Trading Up 2.8%

NASDAQ:ALLO opened at $1.12 on Wednesday. The firm has a market cap of $386.95 million, a PE ratio of -1.67 and a beta of 0.76. The stock has a fifty day moving average price of $1.58 and a 200 day moving average price of $1.97. Allogene Therapeutics has a 12-month low of $1.04 and a 12-month high of $4.46.

Allogene Therapeutics (NASDAQ:ALLO – Get Free Report) last released its earnings results on Wednesday, August 12th. The company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.17) by $0.04. The company had revenue of $4.64 million for the quarter, compared to analyst estimates of $0.00 million. Equities analysts forecast that Allogene Therapeutics will post -0.58 EPS for the current year.

Insider Buying and Selling

In other Allogene Therapeutics news, SVP Earl Douglas sold 29,697 shares of the stock in a transaction that occurred on Friday, August 21st. The shares were sold at an average price of $2.12, for a total value of $62,957.64. Following the sale, the senior vice president directly owned 488,267 shares of the company’s stock, valued at approximately $1,035,126.04. This represents a 5.73% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Geoffrey M. Parker sold 36,342 shares of the stock in a transaction that occurred on Wednesday, October 21st. The shares were sold at an average price of $1.34, for a total transaction of $48,698.28. Following the completion of the sale, the chief financial officer directly owned 1,045,877 shares in the company, valued at approximately $1,401,475.18. This represents a 3.36% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 13.20% of the stock is owned by insiders.

Institutional Investors Weigh In On Allogene Therapeutics

Institutional investors have recently modified their holdings of the company. BlackRock Inc. acquired a new position in shares of Allogene Therapeutics during the second quarter worth $62,706,000. Frazier Life Sciences Management L.P. raised its stake in Allogene Therapeutics by 491.2% in the second quarter. Frazier Life Sciences Management L.P. now owns 22,446,668 shares of the company’s stock valued at $46,689,000 after buying an additional 18,650,000 shares in the last quarter. Primecap Management Co. CA acquired a new stake in Allogene Therapeutics in the second quarter valued at $27,297,000. Candriam S.C.A. raised its stake in Allogene Therapeutics by 25.1% in the third quarter. Candriam S.C.A. now owns 5,422,820 shares of the company’s stock valued at $8,708,000 after buying an additional 1,086,524 shares in the last quarter. Finally, Walleye Capital LLC purchased a new stake in Allogene Therapeutics during the 2nd quarter worth about $6,797,000. 83.63% of the stock is owned by hedge funds and other institutional investors.

Allogene Therapeutics Company Profile

(Get Free Report)

Allogene Therapeutics, Inc is a clinical-stage biotechnology company focused on developing allogeneic, or “off-the-shelf,” CAR T cell therapies for cancer. Unlike conventional autologous CAR T treatments, which are manufactured from an individual patient’s own cells, Allogene’s approach uses healthy donor cells that can potentially be produced in advance and administered more quickly.

The company’s investigational pipeline has included cemacabtagene ansegedleucel (cema-cel, formerly ALLO-501A) for certain patients with large B-cell lymphoma, as well as other allogeneic CAR T candidates being studied in blood cancers such as multiple myeloma and in solid tumors, including renal cell carcinoma.